RINVOQ is an oral selective and reversible JAK inhibitor indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.1
One dose, one tablet,
once a day
Once-daily oral treatment for your adult patients with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
Download the prescribing guide to get started
Dosing recommendations1
The recommended dose of RINVOQ in active PsA is one 15-mg tablet once a day, with or without food
The tablet should be swallowed whole, and should not be split, crushed, or chewed
Take RINVOQ at the
same time every day
RINVOQ can be taken as monotherapy or in combination with methotrexate.
Upadacitinib is metabolized mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medicinal products that strongly inhibit (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, and clarithromycin) or induce (rifampin and phenytoin) CYP3A4. Consider alternatives to strong CYP3A4 inhibitors when used in the long term. Patients should be monitored for changes in disease activity if upadacitinib is co-administered with strong CYP3A4 inducers.
Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.
You may also be interested in
I want to receive more information
via a product specialist.
I have a question for
Medical Information.
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG.